ASH 2022 | Future treatment strategies for R/R Ph+ ALL
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the potential treatment algorithms for relapsed/refractory (R/R) Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Dr Levis highlights the difficulties with treating relapsed ALL patients who have already undergone therapy but are ineligible for allogeneic transplant, and further emphasizes the importance of novel immunotherapeutic agents, such as antibody-drug conjugates (ADCs). This interview took place at the 64th ASH Annual Meeting and Exposition Congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
